tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Christopher Neyor, 10 are a BUY (90.91%), 1 are a SELL (9.09%).
Analyst Christopher Neyor, currently employed at JPMORGAN, carries an average stock price target met ratio of 8.33% that have a potential upside of 9.1% achieved within 80 days.
Christopher Neyor’s has documented 21 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on PCRX, Pacira Pharmaceuticals at 12-Aug-2024.
Analyst best performing recommendations are on PCRX (PACIRA PHARMACEUTICALS).
The best stock recommendation documented was for PCRX (PACIRA PHARMACEUTICALS) at 7/26/2021. The price target of $75 was fulfilled within 239 days with a profit of $16.09 (27.31%) receiving and performance score of 1.14.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$32
$5.55 (20.98%)
$32
1 months 1 days ago
(08-Apr-2025)
4/20 (20%)
$5.73 (21.81%)
496
Buy
$65
$38.55 (145.75%)
$70
1 months 1 days ago
(08-Apr-2025)
13/29 (44.83%)
$38.73 (147.43%)
233
Hold
$18
$-8.45 (-31.95%)
$18
3 months 25 days ago
(14-Jan-2025)
1/11 (9.09%)
$-2.55 (-12.41%)
11
Hold
$17
$-9.45 (-35.73%)
$25
5 months 27 days ago
(12-Nov-2024)
4/12 (33.33%)
$0.2 (1.19%)
270
Buy
$18
$-8.45 (-31.95%)
$30
7 months 15 days ago
(24-Sep-2024)
1/4 (25%)
$3.74 (26.23%)
71
What Year was the first public recommendation made by Christopher Neyor?
